Zymar is a drug owned by Allergan Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 20, 2020. Details of Zymar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6333045 (Pediatric) | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Feb, 2020
(4 years ago) |
Expired
|
| US6333045 | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Aug, 2019
(5 years ago) |
Expired
|
|
US5880283 (Pediatric) | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Jun, 2016
(8 years ago) |
Expired
|
| US5880283 | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Dec, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Zymar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zymar's family patents as well as insights into ongoing legal events on those patents.
Zymar's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zymar's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 20, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zymar Generic API suppliers:
Gatifloxacin is the generic name for the brand Zymar. 6 different companies have already filed for the generic of Zymar, with Apotex Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zymar's generic
How can I launch a generic of Zymar before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Zymar's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Zymar's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Zymar -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.003 | 19 Jul, 2007 | 1 | 19 Aug, 2011 | 20 Aug, 2019 | Eligible |
Alternative Brands for Zymar
There are several other brand drugs using the same active ingredient (Gatifloxacin) as Zymar. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Gatifloxacin, Zymar's active ingredient. Check the complete list of approved generic manufacturers for Zymar
About Zymar
Zymar is a drug owned by Allergan Inc. Zymar uses Gatifloxacin as an active ingredient. Zymar was launched by Allergan in 2003.
Approval Date:
Zymar was approved by FDA for market use on 28 March, 2003.
Active Ingredient:
Zymar uses Gatifloxacin as the active ingredient. Check out other Drugs and Companies using Gatifloxacin ingredient
Dosage:
Zymar is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.3% | SOLUTION/DROPS | Discontinued | OPHTHALMIC |